We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
Read MoreHide Full Article
MyoKardia, Inc. announced that it has dosed the first patient in a phase I study evaluating its pipeline candidate MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM). Top-line data from the study is expected in mid-2020.
The early-stage study will evaluate the safety, tolerability and pharmacokinetics of MYK-224 for treating HCM, a progressive disease wherein excessive contraction of the heart muscle and reduced ability of the left ventricle to fill blood lead to cardiac dysfunction, such as heart failure and sudden cardiac arrest.
Per the company, patients experiencing symptoms of HCM presently have no adequate pharmacologic treatment options to access. MYK-224 looks to address this issue with its distinct physicochemical properties that may provide dosing with certain advantages for the given patient population.
Shares of MyoKardia have rallied 14.1% so far this year versus the industry’s decline of 1.2%.
MyoKardia is a clinical stage biopharmaceutical company that discovers and develops therapies for the treatment of rare cardiovascular diseases.
The company uses precision medicine approach to develop its therapeutic candidates for addressing such patient populations. Apart from MYK-224, MyoKardia has two pipeline candidates in its portfolio, namely mavacamten and MYK-491, which are in mid-to-late-stage development for treating HCM and dilated cardiomyopathy (DCM), respectively.
MyoKardia’s lead therapeutic candidate for HCM is mavacamten. It is currently being evaluated in the phase III EXPLORER-HCM study for treating obstructive HCM and a phase II MAVERICK-HCM study for non-obstructive HCM. Top-line data from the EXPLORER-HCM study is expected in the second quarter of 2020 while the same from the MAVERICK-HCM study is expected later this year.
Meanwhile, the company is evaluating MYK-491 in phase IIa multiple-ascending dose study for addressing patients with stable systolic heart failure. Data from this study is also anticipated later this year.
Alexion’s earnings estimates have been revised 4.2% upward for 2019 and 2.1% for 2020 over the past 60 days. The stock has rallied 18% year to date.
Compugen’s loss per share estimates have been narrowed 16.7% for 2019 and 16.3% for 2020 over the past 60 days. The stock has soared 83% year to date
Alder BioPharmaceuticals’ loss per share estimates have been narrowed 6.8% for 2019 and 2.6% for 2020 over the past 60 days.
It’s Illegal in 42 States, But Investors Will Make Billions Legally
In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year.
That’s twice as much as they spend on marijuana, legally or otherwise.
Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.
Image: Bigstock
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
MyoKardia, Inc. announced that it has dosed the first patient in a phase I study evaluating its pipeline candidate MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM). Top-line data from the study is expected in mid-2020.
The early-stage study will evaluate the safety, tolerability and pharmacokinetics of MYK-224 for treating HCM, a progressive disease wherein excessive contraction of the heart muscle and reduced ability of the left ventricle to fill blood lead to cardiac dysfunction, such as heart failure and sudden cardiac arrest.
Per the company, patients experiencing symptoms of HCM presently have no adequate pharmacologic treatment options to access. MYK-224 looks to address this issue with its distinct physicochemical properties that may provide dosing with certain advantages for the given patient population.
Shares of MyoKardia have rallied 14.1% so far this year versus the industry’s decline of 1.2%.
MyoKardia is a clinical stage biopharmaceutical company that discovers and develops therapies for the treatment of rare cardiovascular diseases.
The company uses precision medicine approach to develop its therapeutic candidates for addressing such patient populations. Apart from MYK-224, MyoKardia has two pipeline candidates in its portfolio, namely mavacamten and MYK-491, which are in mid-to-late-stage development for treating HCM and dilated cardiomyopathy (DCM), respectively.
MyoKardia’s lead therapeutic candidate for HCM is mavacamten. It is currently being evaluated in the phase III EXPLORER-HCM study for treating obstructive HCM and a phase II MAVERICK-HCM study for non-obstructive HCM. Top-line data from the EXPLORER-HCM study is expected in the second quarter of 2020 while the same from the MAVERICK-HCM study is expected later this year.
Meanwhile, the company is evaluating MYK-491 in phase IIa multiple-ascending dose study for addressing patients with stable systolic heart failure. Data from this study is also anticipated later this year.
Zacks Rank & Stocks to Consider
MyoKardia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Alexion Pharmaceuticals, Inc. , Compugen Ltd. (CGEN - Free Report) and Alder BioPharmaceuticals, Inc. , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alexion’s earnings estimates have been revised 4.2% upward for 2019 and 2.1% for 2020 over the past 60 days. The stock has rallied 18% year to date.
Compugen’s loss per share estimates have been narrowed 16.7% for 2019 and 16.3% for 2020 over the past 60 days. The stock has soared 83% year to date
Alder BioPharmaceuticals’ loss per share estimates have been narrowed 6.8% for 2019 and 2.6% for 2020 over the past 60 days.
It’s Illegal in 42 States, But Investors Will Make Billions Legally
In addition to the companies you read about above, today you get details on the newly-legalized
industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year.
That’s twice as much as they spend on marijuana, legally or otherwise.
Zacks special report revealing how investors can profit from this new opportunity. As more states
legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special
Report revealing 5 top stocks to watch in this space.
See these 5 “sin stocks” now>>